genflow biosciences
longer better life

# CORPORATE
# OVERVIEW

March 2026

LSE: **GENF** - OTCQB: **GENFF**

# FORWARD LOOKING STATEMENTS

This presentation contains express or implied information and statements that might be deemed forward-looking information and statements in respect of Genflow Biosciences. They do not constitute historical facts.

Certain information and statements include financial projections that are based upon certain assumptions and assessments made by Genflow Biosciences' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the Genflow Biosciences' management believes that the forward-looking statements and information are reasonable, the Genflow Biosciences' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of Genflow Biosciences. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by Genflow Biosciences with the AMF. Such forward-looking statements are not guarantees of future performance.

This presentation includes only summary information and should be read with the Genflow Biosciences Universal Registration Document filed with the AMF on 15 April 2022 including the 2021 Financial results, all available on the Genflow Biosciences' website. Other than as required by applicable law, Genflow Biosciences issues this presentation at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. This presentation does not constitute an offer to sell the shares or soliciting an offer to purchase any of the Shares to any person in any jurisdiction where such an offer or solicitation is not permitted. The Shares may not be offered or sold, directly or indirectly, may be distributed or sent to any person or into any jurisdiction, except in circumstances that will result in the compliance with all applicable laws and regulations.

Persons into whose possession this presentation may come are required to inform themselves about, and to observe all, such restrictions. The Company accept no responsibility for any violation by any person, whether or not it is a prospective purchaser of Shares, of any such restriction. The information contained in this presentation has not been independently verified and no commitment, representation or warranty, express or implied, is given by the Company or anyone of its directors, officers or respective affiliates or any other person and may not serve as the basis for the veracity, completeness, accuracy or completeness of the information contained in this document (or for any omission of any information in this presentation) or any other information relating to the Company or its affiliates.

The information contained in this document is provided only as of the date of this document and may be subject to update, supplement, revision, verification and modification. They can be modified significantly. The Company is not subject to an obligation to update the information contained in this document and any opinion expressed in this document is subject to change without notice. The Company, its advisers, its representatives cannot be held responsible in any manner whatsoever for any loss of any nature whatsoever resulting from the use of this document or its contents or otherwise related in any way to this document.

This document contains information relating to the Company's markets and the positioning of the Company in these markets. This information is derived from various sources and estimates of the Company. Investors cannot rely on this information to make their investment decision.

# WHO WE ARE
## Pioneering Novel Gene Therapeutics for a Longer Healthier Life

genflowbiosciences
longer better life

### MISSION
We develop gene therapies that target aging at its source—slowing or halting the process in humans and dogs.
By tackling aging, the root driver of many diseases, we turn breakthroughs in longevity science into treatments for age-related conditions.

### PROPRIETARY CENT SIRT6 GENE
Centenarian SIRT6 (cent SIRT6)
Proprietary variant found in long-lived humans that enhances DNA repair, metabolism regulation, and stress resistance.

### PRECLINICAL RESULTS
Lead candidate GF-1002 delivers cent SIRT6 via LNPs for advanced MASH.
Strong preclinical efficacy in fibrosis reduction, inflammation, liver function and Carcinoma prevention.

### EXPERIENCED TEAM
Seasoned management with 30+ years in public and private biotech (Nasdaq, OMX), plus a world-class Scientific Advisory Board across aging, NASH, and ophthalmology.

### ROBUST PIPELINE
Multiple programs advancing over 24 months:
MASH (GF-1002)
Anti-aging Dogs (GF-1004)
Glaucoma (GF-1006)
Sarcopenia (GF-1005)
Werner Syndrome (GF-1003)

LSE: **GENF** - OTCQB: **GENFF**

# SCIENTIFIC ADVISORY BOARD

genflow biosciences
longer better life

**DR. VERA GORBUNOVA, PHD**

CO Director

Rochester Aging Research Center
Affiliated With
Weizmann Institute Of Science



**DR. ERIC VERDIN MD/PHD**

CEO & President

Buck Institute
Affiliated With
UCSF School Of Medicine

**DR. MATTHEW HIRSCHEY, PHD**

Assistant Professor

Duke University School of Medicine
Affiliated With
American Heart Association

**DR. MANLIO VINCIGUERRA, PHD**

Principle Investigator

University of Liverpool
Affiliated With
UCL

**PROF. DR. SVEN FRANCQUE, PHD**

NASH Expert

University of Antwerp

**DR. MARY RINELLA, MD**

NASH Expert

University of Chicago Medicine

Affiliated with

Affiliated with

Affiliated with

LSE: **GENF** - OTCQB: **GENFF**

# MANAGEMENT

## GAD BERDUGO

### Chairperson

- Managing Partner of Explorium Capital with 35+ years of leadership across global biotech business & corporate development, venture management and U.S. capital markets with a proven record at structuring and closing partnerships and capital raises
- Former C-level executive at private and public biotech companies, with financial advisory and investment management experience from Lazard and Tegris
- Graduated from Imperial College London, University College London, and HEC Paris



## DR ERIC LEIRE MD MBA

### Founder & CEO

- MD and MBA, Eric has been involved in biotech for over 30 years
- Research position at Harvard University. Held senior positions including CEO of publicly traded biotech companies (Nasdaq, OTC.QB, OMX.Nasdaq)
- Inventor of several patents and author of medical peer-reviewed publications

LSE: **GENF** - OTCQB: **GENFF**

# GENE REGULATION IN AGING

Aging is a function of overworked epigenetic regulator genes unable to respond to cellular DNA damage

MANY GENES REGULATE AGING.
OUR FOCUS IS THE CENTENARIAN **SIRT6 (cent SIRT6) GENE**




genflow biosciences

LSE: **GENF** - OTCQB: **GENFF**

Aging is driven by interlinked Hallmarks, all rooted in DNA damage. Targeting one individual factor is unlikely to be effective



# WHY SIRT6

Master regulator of DNA repair, metabolism, inflammation, aging

Centenarian SIRT6 variant with enhanced activity

Broad relevance across liver, retina, systemic aging

**SIRT6:** REPAIRING DNA




5 different amino acids between SIRT6 protein of mouse and of naked mole rat

c

Source: Tian et al., 2019, Cell 177, 622–638 April 18, 2019

# SIRT6CENT EDGE:CENTENARIAN GENETICS VALIDATED BENEFIT

Sirtuins are a family of highly conserved signaling proteins involved in metabolic regulation and implicated in influencing cellular processes incl. aging,

Sirtuin 6 (SIRT6 ) is a stress responsive NAD+-dependent histone deacetylase (HDAC) promoting increased longevity

A new allelic variant of human SIRT6 with two point mutations (N308K/A313S) was recently associated with the longevity in Ashkenazi Jews (SIRT6cent)

SIRT6cent confers various benefits, such as increased DNA repair capacity, enhanced metabolic regulation, and improved stress resistance.








Article

THE EMBO JOURNAL

SOURCE DATA | TRANSPARENT PROCESS | OPEN ACCESS

A rare human centenarian variant of SIRT6 enhances genome stability and interaction with Lamin A

Matthew Simon[1,†], Jiping Yang[2,†], Jonathan Gigas[1], Eric J Earley[3], Eric Hillpot[1], Lei Zhang[4], Maria Zagorulya[1], Greg Tombline[1], Michael Gilbert[5], Samantha L Yuen[4], Alexis Pope[2], Michael Van Meter[1], Stephan Emmrich[1], Denis Firsanov[1], Advait Athreya[1], Seyed Ali Biashad[1], Jeehae Han[6], Seungjin Ryu[6], Archana Tare[6], Yizhou Zhu[6], Adam Hudgins[6], Gil Atzmon[6,7], Nir Barzilai[6], Aaron Wolfe[8], Kelsey Moody[8], Benjamin A Garcia[5], David D Thomas[4], Paul D Robbins[4], Jan Vijg[6], Andrei Seluanov[1,*], Yousin Suh[2,**] & Vera Gorbunova[1,***]

## SIRT6c vs SIRT6wt properties

Enzymatic activity: SIRT6c displays stronger mono-ADP-ribosyl transferase.
Genomic stability/ DNA repair: Improved genome maintenance and DNA repair (Simon et al. EMBO, 2022).
Anti-fibrotic effects:

- Down-regulation of profibrotic genes expression
- Reduced Col1A1 deposition in fibrotic conditions
- Reduced hepatocytes cell stiffness

Anti-inflammatory effects: Down-regulation of IL-1b and IL-6 protein
HCC:

- Modulation of ECM-related genes expression
- Increased cell stiffness in hepatoma cells, associated to reduced invasives

Transcriptomic analysis: Differential modulation of b-catenin/TP63 and glucocorticoids pathways



# DEVELOPMENT PIPELINE

## Centenarian SIRT6 Gene Therapy Platform • Priority Programs

genflow biosciences
longer better life

Completed | Ongoing | Planned

| PROGRAM | PRE-CLINICAL | IND-ENABLING | PHASE I/II | PHASE II/III |
|---|---|---|---|---|
| **Anti-Aging Dogs**<br>GF-1004<br>AAV8 / Naked DNA • cent SIRT6<br>*Veterinary Partner* | ✓<br>Completed | ✓<br>Completed | • **ONGOING**<br>Clinical POC<br>Readout Q1 2026 | —<br>Planned |
| **MASH**<br>GF-1002<br>AAV8 • cent SIRT6 (liver)<br>*IND-Enabling Phase* | ✓<br>Completed | • **ONGOING**<br>IND-Enabling<br>18 mo. to FIH | —<br>36 patients | —<br>Planned |
| **Glaucoma**<br>GF-1006<br>LNP-mRNA • cent SIRT6 (retina)<br>*Ophthalmology CRO Partner* | • **ONGOING**<br>Rodent POC<br>Q2 2026 | —<br>Planned | —<br>Planned | —<br>Planned |

GF-1004: Clinical POC readout Q1 2026 — aged dog trial, n=24 beagles, GLP-certified CRO (Syngene) • GF-1002: IND-enabling ongoing; 18 months to first-in-human; 36-patient Phase I/II planned • GF-1006: Pre-clinical rodent POC Q2 2026 with Ophthalmology CRO partner

# RATIONALE FOR SIRT6 USE TO EXTEND LIFESPAN

## SIRT6 transgenic mice

### SIRT6 knockout(KO)




### SIRT6 Overexpression(OE)




Cell. 2006 Jan 27;124(2):315-29.

# RATIONALE FOR SIRT6 USE IN AGED DOGS

## SIRT6 OE in aged cells reverses epigenetic age (DNA mAge)






# RATIONALE FOR SIRT6 USE IN SARCOPENIA

## Genflow SIRT6 study conducted with Rochester University, NY

### Frailty Test in Mice

Centenarian SIRT6 demonstrates statistically significant improvement



# AGED DOGS COMPARATIVE TRIAL (SLAB)

## Proof-of-Concept: in-vivo randomized blinded naked DNA gene therapy in aged beagles

genflow biosciences
longer better life

| TRIAL DESIGN | |
|---|---|
| **CRO** | Syngene (GLP-certified facility) |
| **Animals** | 26 aged Beagles (24 + 2 reserve), age > 10 years |
| **Treatment** | 180-day treatment + 90-day follow-up |
| **Blinded readout** | First interim clinical readout January 2026: promising preliminary clinical results |

| KEY ENDPOINTS (Q2 2026) | |
|---|---|
| **Epigenetic age** | Pan-mammalian methylation clock (GrimAge) |
| **Sarcopenia** | Muscle biopsies + functional frailty testing |
| **Biomarkers** | Markers of aging, inflammation, metabolism |
| **Safety** | Excellent profile confirmed in all treated animals |

| TREATMENT GROUPS (n=6 per group) | |
|---|---|
| Group 1 | Untreated control |
| **Group 2** | IV bolus — AAV8 SIRT6 gene therapy |
| **Group 3** | IV infusion — Naked DNA (low dose) |
| **Group 4** | IV infusion — Naked DNA (high dose) |

# NAKED DNA DELIVERY FOR DOGS

## Naked DNA in vivo delivery in small mammals like dogs holds several advantages:

**Safety and Simplicity:** Naked DNA lacks viral components, reducing the risk of immune responses and integration-related mutagenesis, making it safer than viral vectors.

**Cost-Effectiveness:** Unlike complex viral vector production, plasmid DNA is relatively easy and inexpensive to produce.

**Transient Expression:** Naked DNA delivers SIRT6 Cent without permanent integration.

**Intravenous (IV) Administration:** IV injection enables the SIRT6 cent DNA to circulate widely, reaching multiple tissues.



# GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON

## Significant market opportunity

80M people worldwide with glaucoma

Leading cause of irreversible blindness

## The Problem: unmet need for neuroprotection

Current treatments only lower IOP

They don't protect retinal ganglion cells (RGCs)

RGC death is irreversible

NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA / RETINA PRESERVATION




*Cheng J, Keuthan CJ, Esumi N. The many faces of SIRT6 in the retina and retinal pigment epithelium. Front Cell Dev Biol. 2023 Nov 1;11:1244765. doi: 10.3389/fcell.2023.1244765. PMID: 38016059; PMCID: PMC10646311.*

# PARTNERING WITH LNP PROVIDERS

## Paradigm shift to retinal protection

- Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma / optic neuropathy models
- Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal

## IVT delivery is now tractable

- Ophtalmology LNPs are removing a major historical barrier for in vivo mRNA therapeutics to reach retina/RGCs

## Clear decision point

A single well-designed rodent POC conducted with IRIS Pharma that shows

- focal RGC expression of SIRT6 cent
- preserved RGC counts and
- preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work.

# ADVANCED MASH PROGRAM

**Affects est. 35 million people globally**

Increasing prevalence

**Significant unmet medical need for Advanced MASH**

Leading cause of chronic liver disease and liver transplant

**Clear regulatory accelerated development pathway**

**Multi-pathway disease modification**

Liver-targeted mRNA/LNP delivery

**SIRT6cent Validated Benefits:**

- Enhanced DNA repair capacity and genomic stability
- Anti-fibrotic effects: reduced Col1A1 deposition and hepatocyte stiffness
- Anti-inflammatory: downregulation of IL-1β and IL-6
- HCC prevention: modulation of ECM-related genes, reduced invasiveness




*Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016 Dec;65(6):1245-1257.*
*Vlad Ratziu, Sven Francque, Arun Sanyal, Breakthroughs in therapies for NASH and remaining challenges, Journal of Hepatology, Volume 76, Issue 6, 2022*

LSE: **GENF** - OTCQB: **GENFF**

# 2026 KEY MILESTONES

## Large & Expanding Market

- Advanced MASH: High unmet needs, rising prevalence
- Gateway to broader anti-aging indication
- Ophthalmology: 80M people with glaucoma worldwide
- 2 new grants awarded in 2024 expanding research pipeline

## Growing IP Portfolio

- 2 proprietary patent families: cent SIRT6 & gene delivery
- Both patent families entering National Phase (PCT)
- Additional patent applications in preparation
- Long patent life protecting competitive position

## mRNA / LNP Delivery Platform

- LNPs delivering cent SIRT6 mRNA to liver & retina
- AI partnership with Heureuka Labs (Duke) for genomics
- Non-viral vector platform for ophthalmology
- Scalable, cost-effective manufacturing pathway

## Near-Term Clinical Catalysts

- GF-1004: Aged dog trial readout Q1 2026 (n=24, Syngene CRO)
- GF-1006: Glaucoma rodent POC Q2 2026 with CRO partner
- GF-1002: IND-enabling phase; 18 months to first-in-human
- Partnerships under CDA with animal health companies

# VALUE INFLECTION TIMELINE

## Upcoming catalysts expected to drive significant value creation in 2026–27

genflow biosciences
longer better life

### Q1 2026

**Aged Dog Trial Interim Readout**

Pan-mammalian epigenetic age clock (GrimAge) + sarcopenia endpoints in 24 aged beagles at GLP-certified CRO (Syngene)

### Q2 2026

**Glaucoma Rodent POC**

Retinal expression of cent SIRT6
RGC count and function preservation
Safety
Go/no-go decision for IND-enabling

### 2026–27

**MASH IND-Enabling → IND-Ready**

18 months to first-in-human
36-patient Phase I/II trial planned
potential pharma acquisition or partnership

# THANK YOU

## Contacts


**CEO, GENFLOW BIOSCIENCES**

Dr. Eric Leire: +32 477 495 881

**HARBOR ACCESS INVESTOR RELATIONS**

Jonathan Paterson : +1 475 477 9401

**GENFLOW BIOSCIENCES SRL**

Biopark Gosselies

Clement Ader 10

6041 Gosselies, Belgium

**GENFLOW BIOSCIENCES Plc**

6 Heddon Street

London W1B 4BT UK

**GENFLOW BIOSCIENCES INC.**

Harvard Square

18 Brattle Street, Suite 400

Cambridge, MA 02138, US


LSE: **GENF** - OTCQB: **GENFF**